DR. ANUJA PATIL

DR. AVNINDRA GUPTA, DR. LALIT VERMA, DR. YUSRA ASAD

Abstract

With improved survival of the patient after the HAART therapy era, the management of CMV retinitis has shifted its course from short-term control of infection to long-term maintenance of vision. The treatment pattern of CMV retinitis has changed drastically after the introduction of valganciclovir. Oral valganciclovir has shown significant response in CMV retinitis and unlike intravenous antivirals, does not require hospitalization. We hereby present a series of six CMV retinitis patients who had a good clinical response with oral valganciclovir. The protocol which we followed in these patients was oral valganciclovir 900mg twice daily for 2-3 weeks followed by 900mg once a day . An improvement in vitritis and retinitis lesions was observed in all six patients. We therefore propose that oral ganciclovir is sufficient in most of the cases and is an efficacious alternative to invasive form of treatment in such cases.